ReviewClinical rheumatology2009
Autoantibodies and other serological markers in rheumatoid arthritis: predictors of disease activity?
Review in Clinical rheumatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 26 citations in OpenAlex.
- Global patterns and predictors of initial treatment in early rheumatoid arthritis: insights from a multinational machine learning study.Clinical rheumatology · 2026Article
- How Were the Elderly RA Patients Doing Over the Past Year?-A Post Hoc Analysis for Telephone Based Following Up to RA Patients in Zunyi China.Journal of inflammation research · 2024Article
- Variations in oral microbiome profiles in rheumatoid arthritis and osteoarthritis with potential biomarkers for arthritis screening.Scientific reports · 2018Article
- Identification of key genes in rheumatoid arthritis and osteoarthritis based on bioinformatics analysis.Medicine · 2018Observational
- Differential proteomic analysis of synovial fluid from rheumatoid arthritis and osteoarthritis patients.Clinical proteomics · 2014Article
- Autoimmunity in chronic obstructive pulmonary disease: clinical and experimental evidence.Expert review of clinical immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The description of potential serological markers of rheumatoid arthritis (RA) activity can be quite useful in optimizing RA treatment, since the laboratory markers currently used, namely erythrocyte sedimentation rate and C-reactive protein, are not specific for RA and are influenced by several other variables. The markers proposed for assessing RA activity include rheumatoid factor, anti-citrullinated protein/peptide antibodies, immunoglobulin M (IgM) anti-IgG advanced glycation end products, markers of bone/cartilage metabolism, mannose-binding lectin, E-selectin, interleukin-6, and leptin. Various studies have investigated the correlation between some of these markers and other variables that might indicate disease activity, e.g., inflammatory activity tests and disease activity scores. However, there is as yet insufficient evidence that any of these markers, in isolation or in combination, are useful in the assessment of RA activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.